Brief: Climb Bio Announces FDA Fast Track Designation For Budoprutug For The Treatment Of Primary Membranous Nephropathy
07/04/2026 12:10
April 7 (Reuters) - Climb Bio Inc CLYM.O: CLIMB BIO ANNOUNCES FDA FAST TRACK DESIGNATION FOR BUDOPRUTUG FOR THE TREATMENT OF PRIMARY MEMBRANOUS NEPHROPATHY CLIMB BIO INC - TO SHARE INITIAL PHASE 2 DATA IN SECOND HALF OF 2026 Source text: ID:nGNX3VpZms Further company coverage: CLYM.O ((Reuters.Briefs@thomsonreuters.com;))